Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial

BACKGROUND: Neoadjuvant chemotherapy followed by surgery is the standard of care for UK patients with locally advanced resectable oesophageal carcinoma (OeC). However, not all patients benefit from multimodal treatment and there is a clinical need for biomarkers which can identify chemotherapy respo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Hale, Matthew D., Nankivell, Matthew, Hutchins, Gordon G., Stenning, Sally P., Langley, Ruth E., Mueller, Wolfram, West, Nicholas P., Wright, Alexander I., Treanor, Darren, Hewitt, Lindsay C., Allum, William H., Cunningham, David, Hayden, Jeremy D., Grabsch, Heike I.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363605/
https://ncbi.nlm.nih.gov/pubmed/27769054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12723
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi